Skip to main content
. 2021 Aug 15;78(4):1067–1079. doi: 10.1161/HYPERTENSIONAHA.121.17567

Figure 3.

Figure 3.

sFLT1 (soluble fms-like tyrosine kinase-1) inhibits vascular smooth muscle cell degradation during spiral artery remodeling. A, At 14.5 days postconception (dpc; B) and 18.5 dpc luminal/total vessel area ratio was decreased upon hsFLT1 (human sFLT1) overexpression (preeclampsia homozygous for hsFLT1 and wild type for rtTA, homozygous for hsFLT1 and heterozygous for rtTA, homozygous for hsFLT1 and homozygous for rtTA) compared with controls (Ctrl/doxycycline [Dox] Ctrl) in decidua and mesometrial triangle (MT). C, Anti-αSMA (α-smooth muscle actin) stained spiral artery in both compartments at 14.5 dpc and (E) at 18.5 dpc; scale bar: 100 µm; arrows = αSMA-positive cells. D, Quantification of αSMA-positive cells revealed persisted vascular smooth muscle cells upon hsFLT1 induction (PE wt, het, and hom) compared with Ctrl (Ctrl/Dox Ctrl), in the MT at 14.5 dpc, (F) and 18.5 dpc. Data are presented as box plot with median, interquartile range±upper/lower extreme; sample size n is listed under each graph respectively; Kruskal-Wallis combined with Dunn multiple comparisons test; *P<0.05, **P<0.01 and ***P<0.001.